Wellington Management Group
XENE icon

Wellington Management Group’s Xenon Pharmaceuticals XENE Stock Holding History

Wellington Management Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86M Sell
1,425,492
-3,404,149
-70% -$189M 0.01% 585
2026
Q1 		$281M Buy
4,829,641
+64,862
+1% +$2.99M 0.05% 303
2025
Q4 		$214M Buy
4,764,779
+1,154,922
+32% +$48.5M 0.04% 375
2025
Q3 		$145M Buy
3,609,857
+1,435,096
+66% +$50.5M 0.03% 461
2025
Q2 		$68.1M Sell
2,174,761
-1,614,436
-43% -$52.7M 0.01% 618
2025
Q1 		$127M Buy
3,789,197
+11,586
+0.3% +$440K 0.02% 454
2024
Q4 		$148M Sell
3,777,611
-65,836
-2% -$2.72M 0.03% 441
2024
Q3 		$151M Buy
3,843,447
+15,226
+0.4% +$614K 0.03% 445
2024
Q2 		$149M Sell
3,828,221
-93,837
-2% -$3.75M 0.03% 449
2024
Q1 		$169M Sell
3,922,058
-240,596
-6% -$11.1M 0.03% 424
2023
Q4 		$192M Buy
4,162,654
+2,434,546
+141% +$86M 0.04% 407
2023
Q3 		$59M Buy
1,728,108
+677,057
+64% +$25.3M 0.01% 651
2023
Q2 		$40.5M Buy
1,051,051
+803,614
+325% +$31.9M 0.01% 765
2023
Q1 		$8.86M Buy
+247,437
New +$9.14M ﹤0.01% 1136

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group's XENE Position: Q2 2026 in Review

Wellington Management Group reduced its Xenon Pharmaceuticals (XENE) stake by 70% in Q2 2026, selling an estimated $189M and leaving 1,425,492 shares worth $86M. The position accounts for 0.01% of the portfolio, ranked #585.

Wellington Management Group first reported a position in XENE in Q1 2023 and has held it in 14 quarters since. The position peaked at $281M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Wellington Management Group held 1,425,492 shares of Xenon Pharmaceuticals worth $86M as of Q2 2026.
  • Wellington Management Group sold 3,404,149 Xenon Pharmaceuticals shares in Q2 2026, an estimated $189M.
  • Xenon Pharmaceuticals made up 0.01% of Wellington Management Group's portfolio in Q2 2026, its #585 holding.
  • Wellington Management Group first reported a position in Xenon Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Wellington Management Group's Xenon Pharmaceuticals position peaked at $281M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.